Delving into the Latest Updates on Anti-GUCY2C chimeric antigen receptor T-cell (Immunochina) with Synapse

Overview

Basic Info

Drug Type

CAR-T

Synonyms

IM96 CAR-T Cell, IM96 CAR-T细胞

Target

GC-C

Mechanism

GC-C antagonists(Heat-stable enterotoxin receptor antagonists), Gene transference, T lymphocyte replacements

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication

Colorectal CancerStomach Cancer

Inactive Indication

Advanced Malignant Solid NeoplasmPancreatic Cancer

Originator Organization

Beijing Imunopharm Technology Co., Ltd.Startup

Active Organization

Beijing Imunopharm Technology Co., Ltd.StartupBeijing Yimiao Medical Technology Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To evaluate the safety of IM96 CAR-T cells in the treatment of patients with advanced colorectal cancer. Secondary objective: To evaluate the efficacy, pharmacokinetic characteristics, and changes in tumor markers of IM96 CAR-T cells in the treatment of patients with advanced colorectal cancer.

Start Date-

Sponsor / Collaborator

Beijing Yimiao Medical Technology Co., Ltd.

NCT06718738

/ RecruitingPhase 1

A Phase I Clinical Study to Evaluate the Safety and Efficacy of IM96 CAR-T Cell Injection in Advanced Colorectal Cancer

This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety and efficacy of IM96 CAR-T cells in treating patients with advanced colorectal cancer

Start Date15 Dec 2024

Sponsor / Collaborator

Beijing Imunopharm Technology Co., Ltd.Startup

[+1]

NCT05287165

/ Unknown statusEarly Phase 1

Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms

This is a open-label, single center to determine the efficacy and safety of IM96 CAR-T cells in Patients With Advanced Digestive System Neoplasms

Start Date10 Mar 2022

Sponsor / Collaborator

Beijing Imunopharm Technology Co., Ltd.Startup

100 Clinical Results associated with Anti-GUCY2C chimeric antigen receptor T-cell (Immunochina)

Login to view more data

100 Translational Medicine associated with Anti-GUCY2C chimeric antigen receptor T-cell (Immunochina)

Login to view more data

100 Patents (Medical) associated with Anti-GUCY2C chimeric antigen receptor T-cell (Immunochina)

Login to view more data

100 Deals associated with Anti-GUCY2C chimeric antigen receptor T-cell (Immunochina)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Cancer	Phase 3	CN	Beijing Imunopharm Technology Co., Ltd.Startup	10 Mar 2022
Advanced Malignant Solid Neoplasm	Phase 2	CN	Beijing Imunopharm Technology Co., Ltd.Startup	10 Mar 2022
Colorectal Cancer	Phase 1	CN	Beijing Imunopharm Technology Co., Ltd.Startup	15 Dec 2024
Stomach Cancer	Phase 1	CN	Beijing Yimiao Medical Technology Co., Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05287165 (ESMO2023) Manual	Phase 1	Advanced Colorectal Adenocarcinoma	9	IM96	(eeusqpybgv) = dtiqknffcq mgdrrfsver (nfczeswytg ) View more	Positive	23 Oct 2023